Smaller studies [12, 24, 31] in patients with CNV secondary to PXE have also reported reduction in CRT with anti-VEGF (including ranibizumab) treatment. The gene discussed is VEGFA; the disease is pseudoxanthoma elasticum (inherited or acquired).